Please login to the form below

Not currently logged in
Email:
Password:

adalimumab-atto

This page shows the latest adalimumab-atto news and features for those working in and with pharma, biotech and healthcare.

Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo

Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo

The FDA has approved Boehringer’s Cyltezo (adalimumab-adbm) as ‘interchangeable’ with Humira (adalimumab) in a landmark ruling. ... adalimumab-atto), Sandoz’s Hyrimoz (adalimumab-adaz), Pfizer’s Abrilada (adalimumab-afzb) and Samsung’s

Latest news

  • New EU and US approvals for Humira biosimilars New EU and US approvals for Humira biosimilars

    Humira (adalimumab) has been the wold's biggest selling drug for years, and made $16bn in sales last year for AbbVie, with a little under $6bn of that total coming from ... It is the second to claim marketing approval in the US market after Amgen's

  • Amgen wins European approval for Humira biosimilar Amgevita Amgen wins European approval for Humira biosimilar Amgevita

    Amgevita (biosimilar adalimumab) is both Amgen’s first biosimilar and now the first Humira biosimilar to be approved in Europe. ... Amgen’s Humira biosimilar was approved last September in the US under the brand name Amjevita (adalimumab-atto), whose

  • Amgen claims first US go-ahead for Humira biosimilar Amgen claims first US go-ahead for Humira biosimilar

    brand. The approval is however just the first step in what is likely to be a long journey before the biosimilar - called Amjevita (adalimumab-atto; formerly ABP 501) - can be prescribed ... Meanwhile AbbVie has already filed a lawsuit against Amgen

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....